Eurofins
Life sciences and food testing laboratory network.
Recent Signals
Aggressive ramp-up in biopharma testing scientists
Eurofins has increased its scientific headcount in its biopharma product testing division by 15% across North America over the last quarter.
Governance Snapshot
Shareholder Ownership
- Gilles Martin (founder)37.20%
- BlackRock Inc4.88%
- The Vanguard Group3.21%
- Norges Bank2.54%
- Other / Undisclosed52.17%
Ownership Concentration
Board Composition
5 board members total
Board Tenure Distribution
Board of Directors
| Name | Role | Type | Since | Nationality | Source | |
|---|---|---|---|---|---|---|
Gilles Martin | Chairman | Non-executive | 2017 | Demo | ||
Member A | Board Member | Independent | 2018 | Demo | ||
Member B | Board Member | Independent | 2019 | Demo | ||
Member C | Board Member | Independent | 2020 | Demo | ||
Member D | Board Member | Independent | 2021 | Demo |
Executive Committee
| Name | Title | Since | Source | |
|---|---|---|---|---|
Chief Executive Officer | Chief Executive Officer | 2016 | Demo | |
Chief Financial Officer | Chief Financial Officer | 2017 | Demo | |
Chief Operating Officer | Chief Operating Officer | 2018 | Demo |
Shareholder Structure
| Shareholder | % Held | Change | As Of | Source | |
|---|---|---|---|---|---|
Gilles Martin (founder) | 37.2% | — | — | Demo | |
BlackRock Inc | 4.88% | — | — | Demo | |
The Vanguard Group | 3.21% | — | — | Demo | |
Norges Bank | 2.54% | — | — | Demo |
Aggressive ramp-up in biopharma testing scientists
Eurofins has increased its scientific headcount in its biopharma product testing division by 15% across North America over the last quarter.
No m&a signals yet
Sources are configured. Intelligence will appear here after the next crawl.
LinkedIn sources not configured
Add scraping sources in the competitor settings to start collecting linkedin intelligence.
Loading hiring data…
Loading technology data…
No expansion signals yet
Sources are configured. Intelligence will appear here after the next crawl.
Verified official source · FY2025 · Official Annual Report
https://www.eurofins.com/en/media-centre/press-releases/2026-01-29/€7.3B
Revenue
+5.0% YoY
24.3%
EBITDA Margin
€1.1B
Free Cash Flow
€1.6B
EBITDA
24.3% margin
65,694
Employees
€3.6B
Net Debt
+4.1%
Organic Growth
Income & Cash Flow Summary · FY2025
Revenue
€7,296M
EBITDA
21.4% of revenue
€1,561M
Net Profit
6.5% of revenue
€473M
Operating Cash Flow
19.2% of revenue
€1,399M
Free Cash Flow
14.7% of revenue
€1,071M
Net Debt
49.9% of revenue
€3,641M
Margin Profile
Revenue vs Peers · FY2025 · Eurofins highlighted
Operating Margin vs Peers · FY2025 — dashed line = 15% benchmark
Intelligence Highlights
Eurofins is the largest company by revenue (€7,296M) and by EBITDA margin (24.3%) in the tracked set.
EBITDA margin of 24.3% far exceeds TIC peers — Eurofins operates a laboratory model with higher fixed-cost leverage.
Net debt of €3,641M (2.3x EBITDA) reflects an aggressive acquisition strategy — largest leverage in the set.
Operating cash flow of €1,399M demonstrates exceptional cash conversion from laboratory infrastructure.
Reports sources not configured
Add scraping sources in the competitor settings to start collecting reports intelligence.